Kento Shionoya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kento Shionoya has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Kazuya Koizumi
Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Kamakura, Japan
10 shared publications - Takao Itoi
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan
10 shared publications Makomo Makazu
Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan
8 shared publicationsMakoto Kako
Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Japan
8 shared publications- Sakue Masuda
Department of Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Kamakura, Japan
8 shared publications - Ryosuke Tonozuka
Department of Gastroenterology and Hepatology Tokyo Medical University Tokyo Japan
7 shared publications
Latest Publications
- Open Access
- 19 July 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (9) , 2817-2825
Prospective Clinical Evaluation of a Novel Repositionable Plastic Stent for Endosonography‐Guided Hepaticogastrostomy With or Without Antegrade Stenting (With Videos)
Background and study aims: A repositionable plastic stent (PS), developed to overcome the limitations of conventional pusher‐type PS in endosonography‐guided hepaticogastrostomy (EUS‐HGS), minimizes the gap between the inner sheath and stent to improve insertability. This prospective single‐center study evaluated its feasibility, safety, and clinical effectiveness in malignant and benign biliary diseases. Patients and Methods: Between August 2022 and August 2024, 100 consecutive patients undergoing EUS‐HGS using the repositionable PS were enrolled. Mechanical tract dilation was performed, and antegrade metal stenting was added when feasible. Results: Trainees performed 76% of the procedures. The median bile duct diameter was 4.3 mm. Technical and functional success rates were 99% and 93.9%, respectively, without need for cautery dilation. Initial PS advancement failed in two benign cases with rigid bile ducts; the stent system was pulled back for additional dilation, enabling successful placement. Adverse events occurred in 10% of cases (biliary peritonitis, 6; cholangitis, 2; biloma from early stent bending, 1; bleeding, 1), all manageable, with intervention required in two cases. No stent migration occurred during the first month after insertion. Recurrent biliary obstruction developed in 24 cases, all with successful reintervention. Median time to recurrence of biliary obstruction was significantly longer for EUS‐HGS combined with antegrade stenting than for EUS‐HGS alone (389 vs. 168 days, p < 0.001). Conclusions: This repositionable PS enables safe, effective EUS‐HGS using mechanical dilation alone and corrective pullback for difficult cases. Its controlled deployment and reliable reintervention support its usefulness in both malignant and benign biliary diseases.
- 19 July 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (9) , 2817-2825
Open AccessProspective Clinical Evaluation of a Novel Repositionable Plastic Stent for Endosonography‐Guided Hepaticogastrostomy With or Without Antegrade Stenting (With Videos)
Background and study aims: A repositionable plastic stent (PS), developed to overcome the limitations of conventional pusher‐type PS in endosonography‐guided hepaticogastrostomy (EUS‐HGS), minimizes the gap between the inner sheath and stent to improve insertability. This prospective single‐center study evaluated its feasibility, safety, and clinical effectiveness in malignant and benign biliary diseases. Patients and Methods: Between August 2022 and August 2024, 100 consecutive patients undergoing EUS‐HGS using the repositionable PS were enrolled. Mechanical tract dilation was performed, and antegrade metal stenting was added when feasible. Results: Trainees performed 76% of the procedures. The median bile duct diameter was 4.3 mm. Technical and functional success rates were 99% and 93.9%, respectively, without need for cautery dilation. Initial PS advancement failed in two benign cases with rigid bile ducts; the stent system was pulled back for additional dilation, enabling successful placement. Adverse events occurred in 10% of cases (biliary peritonitis, 6; cholangitis, 2; biloma from early stent bending, 1; bleeding, 1), all manageable, with intervention required in two cases. No stent migration occurred during the first month after insertion. Recurrent biliary obstruction developed in 24 cases, all with successful reintervention. Median time to recurrence of biliary obstruction was significantly longer for EUS‐HGS combined with antegrade stenting than for EUS‐HGS alone (389 vs. 168 days, p < 0.001). Conclusions: This repositionable PS enables safe, effective EUS‐HGS using mechanical dilation alone and corrective pullback for difficult cases. Its controlled deployment and reliable reintervention support its usefulness in both malignant and benign biliary diseases.
- 19 August 2025
- Published by Wiley in Digestive Endoscopy
- Vol. 37 (11) , 1170-1178
Impact of a Thinner Snare Wire With Optimal Electrosurgical Unit Settings on the Risk of Delayed Bleeding After Endoscopic Papillectomy: A Propensity Score‐Matched Analysis (With Video)
Objectives: The indications for endoscopic papillectomy (EP) have expanded. However, post‐procedural adverse events remain high. We performed ex vivo and clinical studies to determine the usefulness of a thinner snare wire (TSW) for preventing delayed bleeding after EP. Methods: To verify the effect of current flow in the monopolar device, a model of an ampulla lesion was created and then resected using a snare. To examine the coagulation effects produced by varying snare wire diameters, patients who underwent EP for ampullary neoplasms were retrospectively analyzed according to the snare wire diameter in the TSW group and the conventional snare wire (CSW) group. The outcomes were compared after propensity score matching (PSM) to control for selection bias and lack of randomization. Results: In the ex vivo study, thermal denaturation was found to be stronger on the counter electrode plate side. In the clinical study, 102 patients who underwent EP were included (TSW group, n = 52; CSW group, n = 50). The matched cohorts included 29 patients per group. Delayed bleeding was significantly less frequent in the TSW group than in the CSW group after PSM (3.4% vs. 31%; p = 0.012). Although residual lesions tended to be more frequent in the TSW group ( p = 0.053), there were no significant differences in other procedural and pathological outcomes. Conclusions: The coagulation effect produced by current flow cannot be ignored. Using a TSW may decrease the incidence of delayed bleeding. It is important to select both a suitable snare wire diameter and appropriate electrosurgical unit settings.
- 19 August 2025
- Published by Wiley in Digestive Endoscopy
- Vol. 37 (11) , 1170-1178
Impact of a Thinner Snare Wire With Optimal Electrosurgical Unit Settings on the Risk of Delayed Bleeding After Endoscopic Papillectomy: A Propensity Score‐Matched Analysis (With Video)
Objectives: The indications for endoscopic papillectomy (EP) have expanded. However, post‐procedural adverse events remain high. We performed ex vivo and clinical studies to determine the usefulness of a thinner snare wire (TSW) for preventing delayed bleeding after EP. Methods: To verify the effect of current flow in the monopolar device, a model of an ampulla lesion was created and then resected using a snare. To examine the coagulation effects produced by varying snare wire diameters, patients who underwent EP for ampullary neoplasms were retrospectively analyzed according to the snare wire diameter in the TSW group and the conventional snare wire (CSW) group. The outcomes were compared after propensity score matching (PSM) to control for selection bias and lack of randomization. Results: In the ex vivo study, thermal denaturation was found to be stronger on the counter electrode plate side. In the clinical study, 102 patients who underwent EP were included (TSW group, n = 52; CSW group, n = 50). The matched cohorts included 29 patients per group. Delayed bleeding was significantly less frequent in the TSW group than in the CSW group after PSM (3.4% vs. 31%; p = 0.012). Although residual lesions tended to be more frequent in the TSW group ( p = 0.053), there were no significant differences in other procedural and pathological outcomes. Conclusions: The coagulation effect produced by current flow cannot be ignored. Using a TSW may decrease the incidence of delayed bleeding. It is important to select both a suitable snare wire diameter and appropriate electrosurgical unit settings.
- Open Access
- 11 June 2025
- Published by Wiley in Digestive Endoscopy
- Vol. 37 (10) , 1137-1138
Identification of the source of biliary bleeding using a novel ultrathin‐type peroral cholangioscope
Watch a video of this article.
- 11 June 2025
- Published by Wiley in Digestive Endoscopy
- Vol. 37 (10) , 1137-1138
Open AccessIdentification of the source of biliary bleeding using a novel ultrathin‐type peroral cholangioscope
Watch a video of this article.
- Open Access
Evaluating the Usefulness of the Blood Apolipoprotein A2 Isoform Index for Pancreatic Cancer Diagnosis
Background: Early detection of pancreatic cancer using existing tumor markers is challenging, and novel biomarkers are needed. Apolipoprotein A2 (APOA2), which is not directly produced by tumors, may help detect pancreatic cancer through mechanisms distinct from carbohydrate antigen 19-9 (CA 19-9). This study aimed to evaluate the diagnostic performance of the APOA2-isoform (APOA2-i) Index in patients with pancreatic cancer. Methods: Serum levels of the APOA2-i Index and CA 19-9 were measured in 76 patients with pancreatic cancer (Stage 0, n = 5; I, n = 4; II, n = 15; III, n = 19; and IV, n = 33) and 98 patients with non-pancreatic cancer (intraductal papillary mucinous neoplasm, n = 36; chronic pancreatitis, n = 33; pancreatic neuroendocrine neoplasm, n = 8; autoimmune pancreatitis, n = 9; and others, n = 12) to evaluate diagnostic performance. Results: APOA2 showed lower accuracy for advanced (stages II–IV) pancreatic cancer compared to CA 19-9 (sensitivity, 50.7% vs. 83.6%; sensitivity, 77.6% vs. 87.9%), but it provided superior accuracy for early-stage (stages 0 and I) detection (sensitivity, 33.3% vs. 22.2%; specificity, 66.7% vs. 59.4%). Three early-stage pancreatic cancer cases negative for CA 19-9 were detected with the APOA2-i Index, demonstrating high diagnostic accuracy for early-stage pancreatic cancer when both biomarkers are combined (sensitivity, 44.4%; specificity, 46.7%). The multivariate analysis revealed pancreatic cancer to be an independent risk factor for APOA2-i Index positivity (odds ratio [OR]: 3.48, p < 0.001), CA 19-9 positivity (OR: 25.5, p < 0.001), and positivity for either marker (OR: 13.3, p < 0.001). Conclusions: The APOA2-i Index, combined with CA 19-9, may improve early-stage pancreatic cancer detection, especially in challenging cases and for high-risk patient surveillance.
Open AccessEvaluating the Usefulness of the Blood Apolipoprotein A2 Isoform Index for Pancreatic Cancer Diagnosis
Background: Early detection of pancreatic cancer using existing tumor markers is challenging, and novel biomarkers are needed. Apolipoprotein A2 (APOA2), which is not directly produced by tumors, may help detect pancreatic cancer through mechanisms distinct from carbohydrate antigen 19-9 (CA 19-9). This study aimed to evaluate the diagnostic performance of the APOA2-isoform (APOA2-i) Index in patients with pancreatic cancer. Methods: Serum levels of the APOA2-i Index and CA 19-9 were measured in 76 patients with pancreatic cancer (Stage 0, n = 5; I, n = 4; II, n = 15; III, n = 19; and IV, n = 33) and 98 patients with non-pancreatic cancer (intraductal papillary mucinous neoplasm, n = 36; chronic pancreatitis, n = 33; pancreatic neuroendocrine neoplasm, n = 8; autoimmune pancreatitis, n = 9; and others, n = 12) to evaluate diagnostic performance. Results: APOA2 showed lower accuracy for advanced (stages II–IV) pancreatic cancer compared to CA 19-9 (sensitivity, 50.7% vs. 83.6%; sensitivity, 77.6% vs. 87.9%), but it provided superior accuracy for early-stage (stages 0 and I) detection (sensitivity, 33.3% vs. 22.2%; specificity, 66.7% vs. 59.4%). Three early-stage pancreatic cancer cases negative for CA 19-9 were detected with the APOA2-i Index, demonstrating high diagnostic accuracy for early-stage pancreatic cancer when both biomarkers are combined (sensitivity, 44.4%; specificity, 46.7%). The multivariate analysis revealed pancreatic cancer to be an independent risk factor for APOA2-i Index positivity (odds ratio [OR]: 3.48, p < 0.001), CA 19-9 positivity (OR: 25.5, p < 0.001), and positivity for either marker (OR: 13.3, p < 0.001). Conclusions: The APOA2-i Index, combined with CA 19-9, may improve early-stage pancreatic cancer detection, especially in challenging cases and for high-risk patient surveillance.
- 5 March 2025
- Published by Wiley in Digestive Endoscopy
- Vol. 37 (7) , 733-746
Delayed bleeding after endoscopic sphincterotomy in patients receiving anticoagulants
Delayed bleeding after endoscopic sphincterotomy (EST) constitutes a significant adverse event, occurring in ~0.5–5% of patients. The number of patients receiving anticoagulants to prevent cardiovascular and cerebrovascular disease has increased with the aging society worldwide; however, anticoagulants (direct oral anticoagulants [DOACs] and warfarin) are one of the most major risk factors for postprocedure bleeding. This review investigated post‐EST bleeding in anticoagulant users, focusing on risk factors, clinical guidelines, pharmacological characteristics, and the future of post‐EST bleeding. Several clinical guidelines for antithrombotic drug users have been established to prevent postprocedure bleeding; nevertheless, the risk of bleeding is believed to be several times higher than for nondrug users, regardless of clinical guideline compliance. The major problem in this field is that patients who experience delayed bleeding are often receiving multiple antithrombotic drugs, and no parameters that can accurately monitor the anticoagulant effect of DOACs have been identified. Therefore, identifying patients with a generally high‐risk of postprocedure bleeding is crucial. Recently, the plasma level and antifactor Xa activity of factor Xa inhibitors have been investigated in relation to the risk of major bleeding in users. Similar to the prothrombin time‐international normalized ratio for warfarin, plasma levels, and antifactor Xa activity may be useful parameters for monitoring the anticoagulant effect and identifying DOAC users at higher risk of postprocedure bleeding, including post‐EST bleeding. Future studies should stratify the risk of post‐EST delayed bleeding based on a scoring system to prevent this complication.
- 5 March 2025
- Published by Wiley in Digestive Endoscopy
- Vol. 37 (7) , 733-746
Delayed bleeding after endoscopic sphincterotomy in patients receiving anticoagulants
Delayed bleeding after endoscopic sphincterotomy (EST) constitutes a significant adverse event, occurring in ~0.5–5% of patients. The number of patients receiving anticoagulants to prevent cardiovascular and cerebrovascular disease has increased with the aging society worldwide; however, anticoagulants (direct oral anticoagulants [DOACs] and warfarin) are one of the most major risk factors for postprocedure bleeding. This review investigated post‐EST bleeding in anticoagulant users, focusing on risk factors, clinical guidelines, pharmacological characteristics, and the future of post‐EST bleeding. Several clinical guidelines for antithrombotic drug users have been established to prevent postprocedure bleeding; nevertheless, the risk of bleeding is believed to be several times higher than for nondrug users, regardless of clinical guideline compliance. The major problem in this field is that patients who experience delayed bleeding are often receiving multiple antithrombotic drugs, and no parameters that can accurately monitor the anticoagulant effect of DOACs have been identified. Therefore, identifying patients with a generally high‐risk of postprocedure bleeding is crucial. Recently, the plasma level and antifactor Xa activity of factor Xa inhibitors have been investigated in relation to the risk of major bleeding in users. Similar to the prothrombin time‐international normalized ratio for warfarin, plasma levels, and antifactor Xa activity may be useful parameters for monitoring the anticoagulant effect and identifying DOAC users at higher risk of postprocedure bleeding, including post‐EST bleeding. Future studies should stratify the risk of post‐EST delayed bleeding based on a scoring system to prevent this complication.
- Open Access
Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center
Background: Biliary tract cancers (BTCs), including gallbladder and bile duct cancers, have a poor prognosis. Recent advances in chemotherapy, such as using targeted drugs for specific gene mutations, have improved outcomes. Gemcitabine plus cisplatin chemotherapy has been the standard of care for the primary treatment of BTCs, but secondary treatment had not been established until recently. In recent years, durvalumab plus gemcitabine and cisplatin (GCD) chemotherapy is emerging as a promising regimen, although more evidence is needed for its effectiveness. Methods: This retrospective single-center study involved 44 patients receiving GCD treatment between January 2023 and March 2024 with a median follow-up of 10 months. Outcomes focused on overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Results: The overall response rate (ORR) was 23%, and the disease control rate (DCR) was 82%. The overall median OS and PFS were 15.3 and 8.0 months, respectively, with patients receiving primary chemotherapy experiencing longer survival compared to a control group. Patients who did not undergo bile duct drainage had statistically different better OS and PFS. Grade 3 or higher AEs occurred in 54.5% of patients, with neutropenia and biliary infections being common. Conclusions: GCD chemotherapy shows potential as an effective treatment for BTCs. The favorable treatment outcome was the response rate, particularly in primary therapy or those cases with no metastasis. Bile duct management is crucial for improving patient outcomes. GCD chemotherapy has a high response rate, PFS, and OS compared to other forms of chemotherapy.
Open AccessInitial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center
Background: Biliary tract cancers (BTCs), including gallbladder and bile duct cancers, have a poor prognosis. Recent advances in chemotherapy, such as using targeted drugs for specific gene mutations, have improved outcomes. Gemcitabine plus cisplatin chemotherapy has been the standard of care for the primary treatment of BTCs, but secondary treatment had not been established until recently. In recent years, durvalumab plus gemcitabine and cisplatin (GCD) chemotherapy is emerging as a promising regimen, although more evidence is needed for its effectiveness. Methods: This retrospective single-center study involved 44 patients receiving GCD treatment between January 2023 and March 2024 with a median follow-up of 10 months. Outcomes focused on overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Results: The overall response rate (ORR) was 23%, and the disease control rate (DCR) was 82%. The overall median OS and PFS were 15.3 and 8.0 months, respectively, with patients receiving primary chemotherapy experiencing longer survival compared to a control group. Patients who did not undergo bile duct drainage had statistically different better OS and PFS. Grade 3 or higher AEs occurred in 54.5% of patients, with neutropenia and biliary infections being common. Conclusions: GCD chemotherapy shows potential as an effective treatment for BTCs. The favorable treatment outcome was the response rate, particularly in primary therapy or those cases with no metastasis. Bile duct management is crucial for improving patient outcomes. GCD chemotherapy has a high response rate, PFS, and OS compared to other forms of chemotherapy.
- Open Access
- 14 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (S 01) , E427-E428
Percutaneous cyanoacrylate injection with endoscopic closure using an over-the-scope clip for refractory duodenocutaneous fistula
Over-the-scope (OTS) clip is useful for hemostasis in gastrointestinal bleeding or closure of gastrointestinal perforations or leaks [1] [2]. A 67-year-old woman with diabetes mellitus was presented to our hospital with abdominal pain. Abdominal computed tomography (CT) showed free air on the liver surface ([Fig. 1]). Although the site of perforation could not be identified, emergency surgery was performed based on the diagnosis of upper gastrointestinal perforation. A perforation in the anterior wall of the duodenal bulb was found and closed with omental packing. On postoperative day 4, the drainage fluid became intestinal fluid-like, suggesting anastomotic leakage. Reoperation revealed separation of the anastomosis, making closure difficult. A jejunostomy was created, and a drain was placed percutaneously ([Fig. 2]). Subsequent attempts to close the perforation failed due to persistent leakage, leading to an enlarged perforation and formation of a duodenocutaneous fistula. After nutritional management and improvement of the patient’s general condition, the perforation was closed, but the duodenocutaneous fistula persisted ([Fig. 3] and [Fig. 4]). Percutaneous injections of tissue adhesive were unsuccessful. A combined approach using percutaneous cyanoacrylate injection and endoscopic closure was performed. As cyanoacrylate administration is an off-label use, permission was obtained from the hospital ethics committee. The endoscope with the OTS clip attached was inserted, and the fistula was aspirated with the surrounding mucosa, though the mucosal surface was hard to aspirate. The clip was released after confirming sufficient aspiration, followed by percutaneous cyanoacrylate injection through the duodenal fistula site to complete the procedure ([Video 1]). Two months postoperatively, CT of the abdomen showed no duodenocutaneous fistula, and the fistula was closed endoscopically ([Fig. 5]). Percutaneous cyanoacrylate injection combined with endoscopic duodenocutaneous fistula closure was effective for refractory duodenocutaneous fistula. Endoscopy_UCTN_Code_TTT_1AO_2AI Article published online: 19 May 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 14 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (S 01) , E427-E428
Open AccessPercutaneous cyanoacrylate injection with endoscopic closure using an over-the-scope clip for refractory duodenocutaneous fistula
Over-the-scope (OTS) clip is useful for hemostasis in gastrointestinal bleeding or closure of gastrointestinal perforations or leaks [1] [2]. A 67-year-old woman with diabetes mellitus was presented to our hospital with abdominal pain. Abdominal computed tomography (CT) showed free air on the liver surface ([Fig. 1]). Although the site of perforation could not be identified, emergency surgery was performed based on the diagnosis of upper gastrointestinal perforation. A perforation in the anterior wall of the duodenal bulb was found and closed with omental packing. On postoperative day 4, the drainage fluid became intestinal fluid-like, suggesting anastomotic leakage. Reoperation revealed separation of the anastomosis, making closure difficult. A jejunostomy was created, and a drain was placed percutaneously ([Fig. 2]). Subsequent attempts to close the perforation failed due to persistent leakage, leading to an enlarged perforation and formation of a duodenocutaneous fistula. After nutritional management and improvement of the patient’s general condition, the perforation was closed, but the duodenocutaneous fistula persisted ([Fig. 3] and [Fig. 4]). Percutaneous injections of tissue adhesive were unsuccessful. A combined approach using percutaneous cyanoacrylate injection and endoscopic closure was performed. As cyanoacrylate administration is an off-label use, permission was obtained from the hospital ethics committee. The endoscope with the OTS clip attached was inserted, and the fistula was aspirated with the surrounding mucosa, though the mucosal surface was hard to aspirate. The clip was released after confirming sufficient aspiration, followed by percutaneous cyanoacrylate injection through the duodenal fistula site to complete the procedure ([Video 1]). Two months postoperatively, CT of the abdomen showed no duodenocutaneous fistula, and the fistula was closed endoscopically ([Fig. 5]). Percutaneous cyanoacrylate injection combined with endoscopic duodenocutaneous fistula closure was effective for refractory duodenocutaneous fistula. Endoscopy_UCTN_Code_TTT_1AO_2AI Article published online: 19 May 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Open Access
- 7 November 2024
- Published by Wiley in Digestive Endoscopy
- Vol. 37 (4) , 430-431
Neuroendocrine neoplasm of the minor papilla diagnosed with endoscopic ultrasonography‐guided fine‐needle biopsy and curatively resected by endoscopic papillectomy
Watch a video of this article.
- 7 November 2024
- Published by Wiley in Digestive Endoscopy
- Vol. 37 (4) , 430-431
Open AccessNeuroendocrine neoplasm of the minor papilla diagnosed with endoscopic ultrasonography‐guided fine‐needle biopsy and curatively resected by endoscopic papillectomy
Watch a video of this article.
- Open Access
- 15 June 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (12) , 1719-1723
Drug-induced Liver Injury Considered Steroid-resistant and Histologically Diagnosed with Vanishing Bile Duct Syndrome
Vanishing bile duct syndrome (VBDS) is characterized by bile duct degeneration and necrosis, which result in bile duct loss and bile stasis. A 70-year-old man had malaise after receiving celecoxib. Laboratory tests revealed elevated hepatobiliary enzymes. His condition worsened without response to medical treatment, and he was transferred to our hospital. A liver biopsy revealed severe bile duct injury and mild cholestasis. He was diagnosed with celecoxib-induced VBDS and underwent bilirubin adsorption therapy. However, his condition continued to deteriorate, and he died. An autopsy showed that liver regeneration was poor, and bile duct loss was exacerbated. The pathological autopsy findings were consistent with VBDS.
- 15 June 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (12) , 1719-1723
Open AccessDrug-induced Liver Injury Considered Steroid-resistant and Histologically Diagnosed with Vanishing Bile Duct Syndrome
Vanishing bile duct syndrome (VBDS) is characterized by bile duct degeneration and necrosis, which result in bile duct loss and bile stasis. A 70-year-old man had malaise after receiving celecoxib. Laboratory tests revealed elevated hepatobiliary enzymes. His condition worsened without response to medical treatment, and he was transferred to our hospital. A liver biopsy revealed severe bile duct injury and mild cholestasis. He was diagnosed with celecoxib-induced VBDS and underwent bilirubin adsorption therapy. However, his condition continued to deteriorate, and he died. An autopsy showed that liver regeneration was poor, and bile duct loss was exacerbated. The pathological autopsy findings were consistent with VBDS.
- Open Access
- 9 February 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (6) , e36224
Difficulty in the diagnosis of pancreatic cancer based on the initial CT report: A retrospective study
The role of computed tomography (CT) in the initial diagnosis of pancreatic cancer (PC) is well-known. CT reports made by radiologists are important as not all patients with PC are examined by specialists; however, some cases are not identified based on CT reports. Diagnosis via imaging of PC is sometimes difficult, and the diagnostic rate of PC and other pancreatic diseases can vary across radiologists. This study aimed to examine the diagnostic rate of PC in initial CT reports and the details of cases with diagnostic difficulties. This single-centered, retrospective study collected clinical data of 198 patients with histologically diagnosed PC between January 2018 and April 2022. Out of these contrast-enhanced CT was performed in 192 cases. PC was not reported as the main diagnosis in 18 patients (9.4%; 11 men and 7 women). Among these 18 cases, intrapancreatic mass lesions were detected in 3 (1.6%), indirect findings such as bile/pancreatic duct stenosis or dilation were detected in 5 (2.6%), and no PC-related findings were found in 10 (5.2%). The specialists suspected PC in 15 of these 18 cases based on initial CT reports. 17 cases were confirmed by endoscopic ultrasound-fine needle aspiration and one by biopsy after upper gastrointestinal endoscopy. To improve accuracy of its diagnosis, it is important that specialists provide feedback to diagnostic radiologists regarding the findings they did not report. Endoscopic ultrasound-fine needle aspiration should be performed by specialists when there is clinical information which indicates pancreatic disease of any kind.
- 9 February 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (6) , e36224
Open AccessDifficulty in the diagnosis of pancreatic cancer based on the initial CT report: A retrospective study
The role of computed tomography (CT) in the initial diagnosis of pancreatic cancer (PC) is well-known. CT reports made by radiologists are important as not all patients with PC are examined by specialists; however, some cases are not identified based on CT reports. Diagnosis via imaging of PC is sometimes difficult, and the diagnostic rate of PC and other pancreatic diseases can vary across radiologists. This study aimed to examine the diagnostic rate of PC in initial CT reports and the details of cases with diagnostic difficulties. This single-centered, retrospective study collected clinical data of 198 patients with histologically diagnosed PC between January 2018 and April 2022. Out of these contrast-enhanced CT was performed in 192 cases. PC was not reported as the main diagnosis in 18 patients (9.4%; 11 men and 7 women). Among these 18 cases, intrapancreatic mass lesions were detected in 3 (1.6%), indirect findings such as bile/pancreatic duct stenosis or dilation were detected in 5 (2.6%), and no PC-related findings were found in 10 (5.2%). The specialists suspected PC in 15 of these 18 cases based on initial CT reports. 17 cases were confirmed by endoscopic ultrasound-fine needle aspiration and one by biopsy after upper gastrointestinal endoscopy. To improve accuracy of its diagnosis, it is important that specialists provide feedback to diagnostic radiologists regarding the findings they did not report. Endoscopic ultrasound-fine needle aspiration should be performed by specialists when there is clinical information which indicates pancreatic disease of any kind.